Ex-drug exec Shkreli has $40 million trading loss - US

Before you go, we thought you'd like these...
Martin Shkreli Hires Celebrity Lawyer

NEW YORK, Feb 3 (Reuters) - Former pharmaceutical executive Martin Shkreli suffered a roughly $40 million drop in the value of a trading account used to secure his bail following his arrest on securities fraud charges, a U.S. prosecutor said on Wednesday.

At a hearing in federal court in Brooklyn, Assistant U.S. Attorney Winston Paes said the account contained mostly shares of KaloBios Pharmaceuticals Inc, a drug company that Shkreli briefly ran.

KaloBios filed for bankruptcy in December, wiping out most of its equity value. That caused the value of Shkreli's E*Trade brokerage account to drop to $4 million to $5 million, from the $45 million level when it had been frozen, the prosecutor said.

See images of Shkreli's arrest:

5 PHOTOS
Martin Shkreli arrested
See Gallery
Ex-drug exec Shkreli has $40 million trading loss - US
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is belted into an awaiting car after being taken into custody following a securities probe, on Thursday, Dec. 17, 2015 in New York. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, sits in an awaiting car after being taken into custody following a securities probe, on Thursday, Dec. 17, 2015 in New York. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York Thursday, Dec. 17, 2015, after being taken into custody following a securities probe. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York Thursday, Dec. 17, 2015, after being taken into custody following a securities probe. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York Thursday, Dec. 17, 2015, after being taken into custody following a securities probe. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
of
SEE ALL
BACK TO SLIDE
SHOW CAPTION +
HIDE CAPTION

Paes told U.S. District Judge Kiyo Matsumoto that Shkreli may need to post new assets to secure his $5 million bond, which was issued following the 32-year-old's arrest in December.

Shkreli's new laywer, Benjamin Brafman, responded, "There's nothing like an indictment to affect the price of shares even if the shares have significant value."

Shkreli's criminal case arose from his prior management of hedge fund MSMB Capital Management and Retrophin Inc, a biopharmaceutical company where he was chief executive before being fired in 2014.

Prosecutors said Shkreli engaged in a Ponzi-like scheme in which he defrauded investors in MSMB, and misappropriated $11 million in assets from Retrophin to repay them. He has pleaded not guilty.

Shkreli's arrest came soon after Turing Pharmaceuticals, another company he headed at the time, caused a public outcry by raising the price of a drug used to treat a dangerous parasitic infection to $750 from $13.50.

Since his arrest, Shkreli has remained active on social media and given interviews to the press.

Some of that may now end.

Brafman, whose clients have included former International Monetary Fund chief Dominique Strauss-Kahn and rapper Sean "Diddy" Combs, told reporters that as a condition of his hiring, Shkreli was to stop talking to the media.

"We want to try this case in court, not the media," Brafman said.

Shkreli is expected to appear on Thursday at a congressional hearing on drug pricing, and assert his Fifth Amendment right against self-incrimination under the U.S. Constitution.

In a separate case, a federal judge in Manhattan on Tuesday gave preliminary approval to a $3 million class action settlement for Retrophin shareholders, based on many claims at issue in Shkreli's criminal prosecution.


More from AOL.com:
Trump says skipping Fox News debate 'could' have hurt him in Iowa
Georgia executes oldest death row inmate for 1979 murder
'DC Madam' lawyer wants to release names from a black book

Read Full Story

People are Reading